News

April 18, 2018 Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure. MedStar Heart, in partnership with CardioCell, a subsidiary of Stemedica Cell Technologies, pioneered the use of stem cells in regenerative medicine. The trial will use CardioCell’s proprietary mesenchymal stem cells (MSCs), manufactured by Stemedica. The goal is to improve outcomes in patients with heart failure and left ventricular assist devices (LVAD).

MedStar Heart & Vascular Institute has been studying the causes of the progressive deterioration of heart function that patients with heart failure experience over time, as well as the potential therapeutic role of stem cells. “We have developed compelling evidence that one of the major mechanisms leading to progressive myocardial dysfunction in patients with heart failure is the presence of persistent and inappropriate inflammation,” said Stephen Epstein, MD, director of Translational and Vascular Biology Research at MedStar Heart & Vascular Institute. “Of great therapeutic relevance is the fact that MSCs have marked anti-inflammatory effects.” Dr. Epstein and his colleagues demonstrated in mouse models of heart attack and of heart failure that intravenously administered MSCs lead to a magnitude of improved heart function that is unprecedented.

August 04, 2017 Kazakhstan Ministry of Health has approved Stemedica Mesenchymal Stem Cells (hMSC) as new drug for Acute Myocardial Infarction (AMI).

Jul 27, 2016 Stemedica begins first clinical trials in the U.S. using adult allogeneic stem cells to treat Alzheimer’s Disease. Sites: Emory University & University of California, Irvine

May 18, 2016 FDA grants IND approval to Stemedica for a traumatic brain injury phase IIa clinical trial. Clinical trial to study the effects of Stemedica’s proprietary mesenchymal stem cells in patients with traumatic brain injury at Promedica health care systems of Toledo, Ohio.

January 27, 2016: Stemedica cell technologies announces completion of enrollment in phase I/IIa clinical trial for ischemic stroke

November 10, 2015: Stemedica establishes stem cell commercial manufacturing facility

July 14, 2015: Stemedica awarded U.S. patent for transgenic therapeutic stem cells.

June 9, 2015: Stemedica FDA grants IND approval for phase IIa clinical trial using Stemedica’s itMSC therapy to treat Alzheimer’s disease at the University of California, San Diego (UCSD) under principle investigator Douglas Galasko, MD.

March 24, 2015: Stemedica obtains an exclusive worldwide license for stem cell stabilization and preservation technologies.

October 1, 2014: Stemedica issued U.S. patent for composition of stem cells and stem cell factors for their use and manufacture.

August 12, 2014: SanoStem Fiji grants approval for dual cell hMSC and hNSC clinical trial for ischemic stroke in Fiji to SanoStem Global. SanoStem is working on formal FDA approval also before recruiting patients.

April 8, 2014): Stemedica appoints founding director for NIH center for regenerative medicine to its scientific and medical advisory board. Mahendra Rao, MD, PhD, (Mumbai, India) is a researcher known for his work involving human embryonic stem cells and other somatic stem cells. In 2011, Rao was founding director of the national institutes of health (NIH) center for regenerative medicine.

Feb 27, 2014: India DCGI grants 3 patient import licenses to SanoStem for Personal Use in India with use of Stemedica SanoMSC and SanoNSC.

April 30, 2013: Stemedica issued U.S. patent for ectodermal stem cells.